Who is sponsoring NCT05578404?

NCT05578404 is sponsored by Tanta University.

What condition does NCT05578404 study?

NCT05578404 studies Non-Alcoholic Fatty Liver Disease.

What drugs are being tested in NCT05578404?

Interventions: Cholecalciferol, Placebo.

What is the status of NCT05578404?

NCT05578404 is currently COMPLETED.

Last reviewed 2023-11-29 · How we verify

High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease

NCT05578404 PHASE2 COMPLETED

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder with high prevalence in patients suffering from chronic liver diseases \[1\]. NAFLD is characterized by the accumulation of \> 5% of fat deposits in hepatocytes (hepatic steatosis) with no known other reasons for steatosis as excessive alcohol intake.The global prevalence of NAFLD differs depending on the population reaching 13% in Africa, 32% in the Middle East, and 30 % in the United States

Details

Lead sponsor	Tanta University
Phase	PHASE2
Status	COMPLETED
Enrolment	100
Start date	Thu Oct 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Apr 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Cholecalciferol
Placebo

Countries

Egypt